HCFA ADMINISTRATOR NOMINEE VLADECK WOULD BRING BOTH ADMINISTRATIVE AND POLICY
This article was originally published in The Gray Sheet
Executive Summary
HCFA ADMINISTRATOR NOMINEE VLADECK WOULD BRING BOTH ADMINISTRATIVE AND POLICY backgrounds to the top position at the Health Care Financing Administration at a time when Congress and President Clinton are focused on cutting health care costs. The White House announced Bruce Vladeck's nomination for the position of HCFA administrator on March 5. Vladeck, 43, has been president of the United Hospital Fund of New York since 1983, directing the fund's involvement in grant-making, health services research and policy development. Vladeck also is a director of the New York City Health and Hospitals Corporation. Additionally, he serves as co-chair of the New York State Council on Health Care Financing. At the national level, Vladeck has served on the federal Medicare Prospective Payment Assessment Commission since 1986, chairing ProPAC's Subcommittee on Hospital Inpatient Services. He was acting ProPAC chairman during the Clinton transition period while Stuart Altman headed a health care policy development group for the incoming administration. Before joining the United Hospital Fund of New York, Vladeck was assistant VP of the Robert Wood Johnson Foundation. From 1979 until 1982, he was assistant commissioner for health planning and resources development of the New Jersey State Department of Health. A good portion of his experience is in regulatory-oriented programs. For example, Vladeck directed the State Health Planning and Development Agency, where he oversaw the implementation of New Jersey's all-payer, DRG-based hospital prospective payment system. Vladeck received a BA in government from Harvard and an MA and PhD in political science from the University of Michigan. From 1974 to 1979, he was an assistant and associate professor of public health and political science at Columbia University. Among his many advisory affiliations, Vladeck is a member of New York State's AIDS Advisory Council and the Governor's Health Care Advisory Board. He published a book entitled Unloving Care: The Nursing Home Tragedy.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.